CD274 and breast carcinoma: To further validate these findings, we analyzed an independent published scRNA-seq dataset from breast cancer patients treated with a PD-L1 inhibitor plus chemotherapy (GSE266919).28 Notably, despite differences in therapeutic regimens (NK cell therapy vs. PD-L1 inhibitor) and tumor types (pancreatic cancer vs. breast cancer), we still observed that c4-ZEB2 and c10-NCR3 exhibited greater expansion patterns in responders than in nonresponders (Supplementary Fig. 6a, b), which was consistent with the trends in our dataset.